These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 32126120)

  • 41. Balancing access and safety in prescribing opioid agonist therapy to prevent HIV transmission.
    Bachireddy C; Weisberg DF; Altice FL
    Addiction; 2015 Dec; 110(12):1869-71. PubMed ID: 26464200
    [No Abstract]   [Full Text] [Related]  

  • 42. The prevalence and correlates of buprenorphine inhalation amongst opioid substitution treatment (OST) clients in Australia.
    Horyniak D; Dietze P; Larance B; Winstock A; Degenhardt L
    Int J Drug Policy; 2011 Mar; 22(2):167-71. PubMed ID: 21112758
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Patterns of physician prescribing for opioid maintenance treatment in Ontario, Canada in 2014.
    Guan Q; Khuu W; Spithoff S; Kiran T; Kahan M; Tadrous M; Martins D; Leece P; Gomes T
    Drug Alcohol Depend; 2017 Aug; 177():315-321. PubMed ID: 28733101
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Commentary on Hser et al. (2014): to retain or not to retain-open questions in opioid maintenance therapy.
    Soyka M; Hillemacher T
    Addiction; 2014 Jan; 109(1):88-9. PubMed ID: 24438113
    [No Abstract]   [Full Text] [Related]  

  • 45. Methadone versus buprenorphine for the treatment of opioid abuse in pregnancy: science and stigma.
    Holbrook AM
    Am J Drug Alcohol Abuse; 2015; 41(5):371-3. PubMed ID: 26154531
    [TBL] [Abstract][Full Text] [Related]  

  • 46. National and State Treatment Need and Capacity for Opioid Agonist Medication-Assisted Treatment.
    Jones CM; Campopiano M; Baldwin G; McCance-Katz E
    Am J Public Health; 2015 Aug; 105(8):e55-63. PubMed ID: 26066931
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Office-Based Buprenorphine Versus Clinic-Based Methadone: A Cost-Effectiveness Analysis.
    King JB; Sainski-Nguyen AM; Bellows BK
    J Pain Palliat Care Pharmacother; 2016; 30(1):55-65. PubMed ID: 27007583
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Factors associated with the prescribing of buprenorphine or methadone for treatment of opiate dependence.
    Ridge G; Gossop M; Lintzeris N; Witton J; Strang J
    J Subst Abuse Treat; 2009 Jul; 37(1):95-100. PubMed ID: 19004598
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Determinants of interest in extended-released buprenorphine: A survey among 366 French patients treated with buprenorphine or methadone.
    Rolland B; Trojak B; Nourredine M; Bachellier J; Chappuy M; Bendimerad P; Kosim M; Hjelmström P; Meroueh F; Nubukpo P; Brousse G
    Drug Alcohol Depend; 2021 Mar; 220():108492. PubMed ID: 33482572
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Methadone, Buprenorphine, or Detoxification for Management of Perinatal Opioid Use Disorder: A Cost-Effectiveness Analysis.
    Premkumar A; Grobman WA; Terplan M; Miller ES
    Obstet Gynecol; 2019 Nov; 134(5):921-931. PubMed ID: 31599845
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Satisfaction guaranteed? What clients on methadone and buprenorphine think about their treatment.
    Madden A; Lea T; Bath N; Winstock AR
    Drug Alcohol Rev; 2008 Nov; 27(6):671-8. PubMed ID: 19378450
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Patterns in admission delays to outpatient methadone treatment in the United States.
    Gryczynski J; Schwartz RP; Salkever DS; Mitchell SG; Jaffe JH
    J Subst Abuse Treat; 2011 Dec; 41(4):431-9. PubMed ID: 21821378
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Characterization of diverted buprenorphine use among adults entering corrections-based drug treatment in Kentucky.
    Smith KE; Tillson MD; Staton M; Winston EM
    Drug Alcohol Depend; 2020 Mar; 208():107837. PubMed ID: 31951906
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Consumer access to buprenorphine and methadone in certified community behavioral health centers: A secret shopper study.
    Presnall NJ; Butler GC; Grucza RA
    J Subst Abuse Treat; 2022 Aug; 139():108788. PubMed ID: 35534359
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Timing of buprenorphine adoption by privately funded substance abuse treatment programs: the role of institutional and resource-based interorganizational linkages.
    Savage SA; Abraham AJ; Knudsen HK; Rothrauff TC; Roman PM
    J Subst Abuse Treat; 2012 Jan; 42(1):16-24. PubMed ID: 21831565
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Opioid treatment in Ukraine risks losing momentum.
    Bull World Health Organ; 2013 Feb; 91(2):87-8. PubMed ID: 23554519
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Patient perspectives on choosing buprenorphine over methadone in an urban, equal-access system.
    Gryczynski J; Jaffe JH; Schwartz RP; Dušek KA; Gugsa N; Monroe CL; O'Grady KE; Olsen YK; Mitchell SG
    Am J Addict; 2013; 22(3):285-91. PubMed ID: 23617873
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A mixed-methods analysis of patient safety incidents involving opioid substitution treatment with methadone or buprenorphine in community-based care in England and Wales.
    Gibson R; MacLeod N; Donaldson LJ; Williams H; Hibbert P; Parry G; Bhatt J; Sheikh A; Carson-Stevens A
    Addiction; 2020 Nov; 115(11):2066-2076. PubMed ID: 32149443
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Legal and policy changes urgently needed to increase access to opioid agonist therapy in the United States.
    Davis CS; Carr DH
    Int J Drug Policy; 2019 Nov; 73():42-48. PubMed ID: 31336293
    [TBL] [Abstract][Full Text] [Related]  

  • 60. State-Targeted Funding and Technical Assistance to Increase Access to Medication Treatment for Opioid Use Disorder.
    Abraham AJ; Andrews CM; Grogan CM; Pollack HA; D'Aunno T; Humphreys K; Friedmann PD
    Psychiatr Serv; 2018 Apr; 69(4):448-455. PubMed ID: 29241428
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.